BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Bristol-Myers Squibb Company's Revenue by Segment

In fiscal year 2024, Bristol-Myers Squibb Company's revenue by segment (products & services) are as follows:

  • Abecma: $406.00 M
  • Abraxane: $875.00 M
  • Breyanzi: $747.00 M
  • Camzyos: $602.00 M
  • Cobenfy: $10.00 M
  • Eliquis: $13.33 B
  • Krazati: $126.00 M
  • Opdivo: $9.30 B
  • Opdualag: $928.00 M
  • Orencia: $3.68 B
  • Other Growth Brands: $1.61 B
  • Other Legacy Brands: $925.00 M
  • Pomalyst/Imnovid: $3.55 B
  • Reblozyl: $1.77 B
  • Revlimid: $5.77 B
  • Sotyktu: $246.00 M
  • Sprycel: $1.29 B
  • Yervoy: $2.53 B
  • Zeposia: $566.00 M

Learn more about Bristol-Myers Squibb Company’s Revenue by Geography

Check out competitors to Bristol-Myers Squibb Company in a side-by-side comparison.

Explore additional financial metrics for Bristol-Myers Squibb Company.

Continue reading...

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2022, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $388.00 M in revenue, representing 0.85% of its total revenue.
  • Abraxane generated $811.00 M in revenue, representing 1.78% of its total revenue.
  • Breyanzi generated $182.00 M in revenue, representing 0.4% of its total revenue.
  • Camzyos generated $24.00 M in revenue, representing 0.05% of its total revenue.
  • Eliquis generated $11.79 B in revenue, representing 25.82% of its total revenue.
  • Mature Products And All Other generated $1.75 B in revenue, representing 3.83% of its total revenue.
  • Opdivo generated $8.25 B in revenue, representing 18.07% of its total revenue.
  • Opdualag generated $252.00 M in revenue, representing 0.55% of its total revenue.
  • Orencia generated $3.46 B in revenue, representing 7.59% of its total revenue.
  • Pomalyst/Imnovid generated $3.50 B in revenue, representing 7.66% of its total revenue.
  • Reblozyl generated $717.00 M in revenue, representing 1.57% of its total revenue.
  • Revlimid generated $9.98 B in revenue, representing 21.86% of its total revenue.
  • Sotyktu generated $8.00 M in revenue, representing 0.02% of its total revenue.
  • Sprycel generated $2.17 B in revenue, representing 4.74% of its total revenue.
  • Yervoy generated $2.13 B in revenue, representing 4.67% of its total revenue.
  • Zeposia generated $250.00 M in revenue, representing 0.55% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 25.82% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Sotyktu, which represents 0.02% of its total revenue.

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2023, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $472.00 M in revenue, representing 1.1% of its total revenue.
  • Abraxane generated $1.00 B in revenue, representing 2.34% of its total revenue.
  • Breyanzi generated $364.00 M in revenue, representing 0.85% of its total revenue.
  • Camzyos generated $231.00 M in revenue, representing 0.54% of its total revenue.
  • Eliquis generated $12.21 B in revenue, representing 28.5% of its total revenue.
  • Opdivo generated $9.01 B in revenue, representing 21.03% of its total revenue.
  • Opdualag generated $627.00 M in revenue, representing 1.46% of its total revenue.
  • Orencia generated $3.60 B in revenue, representing 8.41% of its total revenue.
  • Pomalyst/Imnovid generated $3.44 B in revenue, representing 8.03% of its total revenue.
  • Reblozyl generated $1.01 B in revenue, representing 2.35% of its total revenue.
  • Revlimid generated $6.10 B in revenue, representing 14.23% of its total revenue.
  • Sotyktu generated $170.00 M in revenue, representing 0.4% of its total revenue.
  • Sprycel generated $1.93 B in revenue, representing 4.51% of its total revenue.
  • Yervoy generated $2.24 B in revenue, representing 5.23% of its total revenue.
  • Zeposia generated $434.00 M in revenue, representing 1.01% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 28.5% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Sotyktu, which represents 0.4% of its total revenue.

The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

In fiscal year 2024, Bristol-Myers Squibb Company's revenue by segment is as follows:

  • Abecma generated $406.00 M in revenue, representing 0.84% of its total revenue.
  • Abraxane generated $875.00 M in revenue, representing 1.81% of its total revenue.
  • Breyanzi generated $747.00 M in revenue, representing 1.55% of its total revenue.
  • Camzyos generated $602.00 M in revenue, representing 1.25% of its total revenue.
  • Cobenfy generated $10.00 M in revenue, representing 0.02% of its total revenue.
  • Eliquis generated $13.33 B in revenue, representing 27.63% of its total revenue.
  • Krazati generated $126.00 M in revenue, representing 0.26% of its total revenue.
  • Opdivo generated $9.30 B in revenue, representing 19.28% of its total revenue.
  • Opdualag generated $928.00 M in revenue, representing 1.92% of its total revenue.
  • Orencia generated $3.68 B in revenue, representing 7.63% of its total revenue.
  • Other Growth Brands generated $1.61 B in revenue, representing 3.33% of its total revenue.
  • Other Legacy Brands generated $925.00 M in revenue, representing 1.92% of its total revenue.
  • Pomalyst/Imnovid generated $3.55 B in revenue, representing 7.35% of its total revenue.
  • Reblozyl generated $1.77 B in revenue, representing 3.67% of its total revenue.
  • Revlimid generated $5.77 B in revenue, representing 11.96% of its total revenue.
  • Sotyktu generated $246.00 M in revenue, representing 0.51% of its total revenue.
  • Sprycel generated $1.29 B in revenue, representing 2.66% of its total revenue.
  • Yervoy generated $2.53 B in revenue, representing 5.24% of its total revenue.
  • Zeposia generated $566.00 M in revenue, representing 1.17% of its total revenue.

The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 27.63% of its total revenue.
The smallest segment for Bristol-Myers Squibb Company is the Cobenfy, which represents 0.02% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2022 2023 2024
Sprycel 4.74% 4.51% 2.66%
Abecma 0.85% 1.1% 0.84%
Abraxane 1.78% 2.34% 1.81%
Breyanzi 0.4% 0.85% 1.55%
Camzyos 0.05% 0.54% 1.25%
Eliquis 25.82% 28.5% 27.63%
Mature Products And All Other 3.83% - -
Opdivo 18.07% 21.03% 19.28%
Opdualag 0.55% 1.46% 1.92%
Orencia 7.59% 8.41% 7.63%
Pomalyst/Imnovid 7.66% 8.03% 7.35%
Reblozyl 1.57% 2.35% 3.67%
Revlimid 21.86% 14.23% 11.96%
Sotyktu 0.02% 0.4% 0.51%
Yervoy 4.67% 5.23% 5.24%
Zeposia 0.55% 1.01% 1.17%
Cobenfy - - 0.02%
Krazati - - 0.26%
Other Growth Brands - - 3.33%
Other Legacy Brands - - 1.92%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Bristol-Myers Squibb Company.

In fiscal year 2024, the Eliquis generated the most revenue ($13.33 B), and the Cobenfy generated the least revenue ($10.00 M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Abecma revenue decreased -13.98% ($66.00 M) from $472.00 M (in 2023) to $406.00 M (in 2024).
  • Abraxane revenue decreased -12.85% ($129.00 M) from $1.00 B (in 2023) to $875.00 M (in 2024).
  • Breyanzi revenue increased 105.22% ($383.00 M) from $364.00 M (in 2023) to $747.00 M (in 2024).
  • Camzyos revenue increased 160.61% ($371.00 M) from $231.00 M (in 2023) to $602.00 M (in 2024).
  • Cobenfy revenue increased 100% ($10.00 M) from $0.00 (in 2023) to $10.00 M (in 2024).
  • Eliquis revenue increased 9.23% ($1.13 B) from $12.21 B (in 2023) to $13.33 B (in 2024).
  • Krazati revenue increased 100% ($126.00 M) from $0.00 (in 2023) to $126.00 M (in 2024).
  • Opdivo revenue increased 3.27% ($295.00 M) from $9.01 B (in 2023) to $9.30 B (in 2024).
  • Opdualag revenue increased 48.01% ($301.00 M) from $627.00 M (in 2023) to $928.00 M (in 2024).
  • Orencia revenue increased 2.25% ($81.00 M) from $3.60 B (in 2023) to $3.68 B (in 2024).
  • Other Growth Brands revenue increased 100% ($1.61 B) from $0.00 (in 2023) to $1.61 B (in 2024).
  • Other Legacy Brands revenue increased 100% ($925.00 M) from $0.00 (in 2023) to $925.00 M (in 2024).
  • Pomalyst/Imnovid revenue increased 3.02% ($104.00 M) from $3.44 B (in 2023) to $3.55 B (in 2024).
  • Reblozyl revenue increased 75.89% ($765.00 M) from $1.01 B (in 2023) to $1.77 B (in 2024).
  • Revlimid revenue decreased -5.31% ($324.00 M) from $6.10 B (in 2023) to $5.77 B (in 2024).
  • Sotyktu revenue increased 44.71% ($76.00 M) from $170.00 M (in 2023) to $246.00 M (in 2024).
  • Sprycel revenue decreased -33.37% ($644.00 M) from $1.93 B (in 2023) to $1.29 B (in 2024).
  • Yervoy revenue increased 13.05% ($292.00 M) from $2.24 B (in 2023) to $2.53 B (in 2024).
  • Zeposia revenue increased 30.41% ($132.00 M) from $434.00 M (in 2023) to $566.00 M (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Abecma $388.00 M - $472.00 M
    21.65%
    		$406.00 M
    13.98%
    Abraxane $811.00 M - $1.00 B
    23.80%
    		$875.00 M
    12.85%
    Breyanzi $182.00 M - $364.00 M
    100.00%
    		$747.00 M
    105.22%
    Camzyos $24.00 M - $231.00 M
    862.50%
    		$602.00 M
    160.61%
    Cobenfy - - - - $10.00 M -
    Eliquis $11.79 B - $12.21 B
    3.54%
    		$13.33 B
    9.23%
    Krazati - - - - $126.00 M -
    Mature Products And All Other $1.75 B - - - - -
    Opdivo $8.25 B - $9.01 B
    9.21%
    		$9.30 B
    3.27%
    Opdualag $252.00 M - $627.00 M
    148.81%
    		$928.00 M
    48.01%
    Orencia $3.46 B - $3.60 B
    3.95%
    		$3.68 B
    2.25%
    Other Growth Brands - - - - $1.61 B -
    Other Legacy Brands - - - - $925.00 M -
    Pomalyst/Imnovid $3.50 B - $3.44 B
    1.60%
    		$3.55 B
    3.02%
    Reblozyl $717.00 M - $1.01 B
    40.59%
    		$1.77 B
    75.89%
    Revlimid $9.98 B - $6.10 B
    38.90%
    		$5.77 B
    5.31%
    Sotyktu $8.00 M - $170.00 M
    2,025.00%
    		$246.00 M
    44.71%
    Sprycel $2.17 B - $1.93 B
    10.85%
    		$1.29 B
    33.37%
    Yervoy $2.13 B - $2.24 B
    5.02%
    		$2.53 B
    13.05%
    Zeposia $250.00 M - $434.00 M
    73.60%
    		$566.00 M
    30.41%
    Total Revenue $45.65 B - $42.83 B
    6.18%
    		$48.26 B
    12.68%

    Frequently Asked Questions

    What was Bristol-Myers Squibb Company's largest product segment last year?

    In fiscal year 2024, Eliquis revenue reached $13.33 Billion, representing 27.63% of Bristol-Myers Squibb Company's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for Bristol-Myers Squibb Company last year?

    The Camzyos segment is Bristol-Myers Squibb Company's highest growth segment, with a revenue growth of +160.61% in 2024 compared to 2023.

    Related company

    Revenue Ranking

    Revenue Ranking

    Related

    Submit feedback to Bullfincher